NZ579341A - Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases - Google Patents
Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinasesInfo
- Publication number
- NZ579341A NZ579341A NZ579341A NZ57934108A NZ579341A NZ 579341 A NZ579341 A NZ 579341A NZ 579341 A NZ579341 A NZ 579341A NZ 57934108 A NZ57934108 A NZ 57934108A NZ 579341 A NZ579341 A NZ 579341A
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenyl
- pyrazol
- tumour
- ethanol
- amino
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- IIRWNGPLJQXWFJ-KRWDZBQOSA-N (1s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)phenyl]ethanol Chemical compound C1([C@](O)(CN)C=2C=CC(=CC=2)C2=CNN=C2)=CC=C(Cl)C=C1 IIRWNGPLJQXWFJ-KRWDZBQOSA-N 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000001685 thyroid gland Anatomy 0.000 abstract 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 abstract 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000003325 follicular Effects 0.000 abstract 2
- 230000003394 haemopoietic effect Effects 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- IIRWNGPLJQXWFJ-QGZVFWFLSA-N (1r)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)phenyl]ethanol Chemical compound C1([C@@](O)(CN)C=2C=CC(=CC=2)C2=CNN=C2)=CC=C(Cl)C=C1 IIRWNGPLJQXWFJ-QGZVFWFLSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 108091008611 Protein Kinase B Proteins 0.000 abstract 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 abstract 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 abstract 1
- 201000010208 Seminoma Diseases 0.000 abstract 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 210000003679 cervix uteri Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 239000011435 rock Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 208000001608 teratocarcinoma Diseases 0.000 abstract 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
- C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
- C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89475207P | 2007-03-14 | 2007-03-14 | |
| GBGB0704932.3A GB0704932D0 (en) | 2007-03-14 | 2007-03-14 | Pharmaceutical compounds |
| PCT/GB2008/050180 WO2008110846A2 (en) | 2007-03-14 | 2008-03-14 | Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ579341A true NZ579341A (en) | 2012-08-31 |
Family
ID=38008428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ579341A NZ579341A (en) | 2007-03-14 | 2008-03-14 | Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20100113551A1 (enExample) |
| EP (2) | EP2433632A1 (enExample) |
| JP (2) | JP2010521446A (enExample) |
| KR (1) | KR20100014720A (enExample) |
| CN (1) | CN101686965B (enExample) |
| AU (1) | AU2008224657B2 (enExample) |
| BR (1) | BRPI0808802A2 (enExample) |
| CA (1) | CA2679878A1 (enExample) |
| CY (1) | CY1115877T1 (enExample) |
| DK (1) | DK2134339T3 (enExample) |
| ES (1) | ES2511817T3 (enExample) |
| GB (1) | GB0704932D0 (enExample) |
| HR (1) | HRP20141034T1 (enExample) |
| IL (1) | IL200822A (enExample) |
| MX (1) | MX2009009874A (enExample) |
| NZ (1) | NZ579341A (enExample) |
| PL (1) | PL2134339T3 (enExample) |
| PT (1) | PT2134339E (enExample) |
| RS (1) | RS53580B1 (enExample) |
| RU (1) | RU2527151C2 (enExample) |
| SI (1) | SI2134339T1 (enExample) |
| WO (1) | WO2008110846A2 (enExample) |
| ZA (1) | ZA200906303B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06007326A (es) | 2003-12-23 | 2007-01-26 | Astex Therapeutics Ltd | Derivados de pirazol como moduladores de proteina cinasa. |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JOP20190231A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| CN106456631A (zh) * | 2014-03-06 | 2017-02-22 | 南加利福尼亚大学 | 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用 |
| RU2657832C1 (ru) * | 2017-06-07 | 2018-06-15 | федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" | Антидиабетическое средство |
| EP3424533A1 (en) * | 2017-07-05 | 2019-01-09 | Nh Theraguix | Methods for treating tumors |
| US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
| MX2022011519A (es) * | 2020-03-25 | 2022-10-07 | Woolsey Pharmaceuticals Inc | Metodos de uso de inhibidores de la quinasa rho para tratar demencia frontotemporal. |
| CN111707830B (zh) * | 2020-07-16 | 2023-08-15 | 首都医科大学附属北京朝阳医院 | Rock激酶活性在辅助诊断肺损害中的应用 |
| WO2025017499A1 (en) | 2023-07-17 | 2025-01-23 | Graviton Bioscience Bv | Formulations and uses of rock2 inhibitors for als |
| WO2025069008A1 (en) | 2023-09-28 | 2025-04-03 | Graviton Bioscience Bv | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| EP0457803A4 (en) | 1989-02-08 | 1991-12-04 | Abbott Laboratories | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5049570A (en) | 1990-01-23 | 1991-09-17 | Du Pont Merck Pharmaceutical Company | Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity |
| FR2707295A1 (fr) | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US5532356A (en) | 1995-06-06 | 1996-07-02 | The Dupont Merck Pharmaceutical Company | Method for preparing N,N'-disubstituted cyclic ureas |
| GB9512961D0 (en) | 1995-06-26 | 1995-08-30 | Pfizer Ltd | Antifungal agents |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0891343A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| GB2314327B (en) | 1996-04-30 | 2000-07-12 | Kodak Ltd | Pyrazolone image dye-forming couplers |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| GB9700555D0 (en) | 1997-01-13 | 1997-03-05 | Merck Sharp & Dohme | Therapeutic agents |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| BR9908522A (pt) | 1998-01-29 | 2001-10-02 | Viropharma Inc | Composto, pró-droga, intermediário para a preparação de um composto, composição farmacêutica, processos para tratar e prevenir infecção por pneumovìrus, para tratar células em cultura, para tratar materiais biológicos, e, para preparar um composto |
| GB9804734D0 (en) | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
| US6291505B1 (en) | 1998-08-07 | 2001-09-18 | Chiron Corporation | Estrogen receptor modulators |
| HN1999000149A (es) | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| US6503905B1 (en) | 1998-12-29 | 2003-01-07 | Pfizer Inc | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| AU4308300A (en) | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| NZ515460A (en) | 1999-05-14 | 2004-06-25 | Neurocrine Biosciences Inc | Imidazo- and pyrrolo[1,2-A]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| IL148698A0 (en) | 1999-09-17 | 2002-09-12 | Cor Therapeutics Inc | INHIBITORS OF FACTOR Xa |
| MX226123B (es) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | Benzamidas e inhibidores del factor xa relacionadas. |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| US6511994B2 (en) | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
| MXPA03009847A (es) | 2001-04-27 | 2004-02-12 | Vertex Pharma | Inhibidores de cinasa derivados de pirazol. |
| MXPA04001087A (es) | 2001-08-03 | 2004-07-08 | Vertex Pharma | Derivados de pirazol como inhibidores de cinasa y uso de los mismos. |
| FR2830192B1 (fr) | 2001-09-28 | 2004-08-20 | Oreal | Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole |
| AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| ES2421511T3 (es) | 2001-12-21 | 2013-09-03 | X Ceptor Therapeutics Inc | Moduladores de LXR |
| DE60330126D1 (de) | 2002-02-14 | 2009-12-31 | Pharmacia Corp | Substituierte pyridinone als modulatoren für p38 map kinase |
| NZ535603A (en) | 2002-03-20 | 2007-10-26 | Metabolex Inc | Substituted phenylacetic acids |
| WO2003086247A1 (en) | 2002-04-08 | 2003-10-23 | Barosense, Inc. | Satiation devices and methods |
| WO2003090680A2 (en) | 2002-04-23 | 2003-11-06 | Axys Pharmaceuticals, Inc. | Novel phenyl derivatives as inducers of apoptosis |
| DK1542997T3 (da) | 2002-07-24 | 2012-06-25 | Dermira Canada Inc | Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler |
| MXPA05002983A (es) | 2002-09-18 | 2005-06-22 | Univ Missouri | Analogos de opiato selectivos del receptor opioide d. |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| MXPA05012281A (es) | 2003-05-14 | 2006-05-19 | Torreypines Therapeutics Inc | Compuestos y uso de los mismos en la modulacion beta amiloide. |
| EP1644365A2 (en) | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| KR101163800B1 (ko) | 2003-10-15 | 2012-07-09 | 산텐 세이야꾸 가부시키가이샤 | 신규 인다졸 유도체 |
| US7750160B2 (en) | 2003-11-13 | 2010-07-06 | Ambit Biosciences Corporation | Isoxazolyl urea derivatives as kinase modulators |
| WO2005061460A1 (en) | 2003-12-08 | 2005-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| RU2419612C2 (ru) * | 2003-12-23 | 2011-05-27 | Астекс Терапьютикс Лимитед | Производные пиразола в качестве модуляторов протеинкиназы |
| MXPA06007326A (es) | 2003-12-23 | 2007-01-26 | Astex Therapeutics Ltd | Derivados de pirazol como moduladores de proteina cinasa. |
| GB0329617D0 (en) * | 2003-12-23 | 2004-01-28 | Astex Technology Ltd | Pharmaceutical compounds |
| US8076338B2 (en) | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| JP5274842B2 (ja) | 2004-12-28 | 2013-08-28 | エグゼリクシス， インコーポレイテッド | 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物 |
| WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| GB2427406A (en) | 2005-06-21 | 2006-12-27 | Astex Technology Ltd | Silicon-containing PKB/PKA kinase inhibitors |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| JP2008543919A (ja) | 2005-06-21 | 2008-12-04 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
| AR054485A1 (es) * | 2005-06-21 | 2007-06-27 | Cancer Rec Tech Ltd | ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5345842B2 (ja) * | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
-
2007
- 2007-03-14 GB GBGB0704932.3A patent/GB0704932D0/en not_active Ceased
-
2008
- 2008-03-14 HR HRP20141034AT patent/HRP20141034T1/hr unknown
- 2008-03-14 JP JP2009553222A patent/JP2010521446A/ja active Pending
- 2008-03-14 EP EP11194939A patent/EP2433632A1/en not_active Withdrawn
- 2008-03-14 MX MX2009009874A patent/MX2009009874A/es active IP Right Grant
- 2008-03-14 US US12/531,013 patent/US20100113551A1/en not_active Abandoned
- 2008-03-14 CN CN200880015813.0A patent/CN101686965B/zh not_active Expired - Fee Related
- 2008-03-14 BR BRPI0808802A patent/BRPI0808802A2/pt not_active IP Right Cessation
- 2008-03-14 WO PCT/GB2008/050180 patent/WO2008110846A2/en not_active Ceased
- 2008-03-14 SI SI200831312T patent/SI2134339T1/sl unknown
- 2008-03-14 AU AU2008224657A patent/AU2008224657B2/en not_active Ceased
- 2008-03-14 DK DK08719025.2T patent/DK2134339T3/da active
- 2008-03-14 CA CA002679878A patent/CA2679878A1/en not_active Abandoned
- 2008-03-14 KR KR1020097020516A patent/KR20100014720A/ko not_active Ceased
- 2008-03-14 EP EP08719025.2A patent/EP2134339B1/en active Active
- 2008-03-14 PL PL08719025T patent/PL2134339T3/pl unknown
- 2008-03-14 RU RU2009137779/04A patent/RU2527151C2/ru not_active IP Right Cessation
- 2008-03-14 NZ NZ579341A patent/NZ579341A/xx not_active IP Right Cessation
- 2008-03-14 PT PT87190252T patent/PT2134339E/pt unknown
- 2008-03-14 RS RSP20140587 patent/RS53580B1/sr unknown
- 2008-03-14 ES ES08719025.2T patent/ES2511817T3/es active Active
-
2009
- 2009-09-08 IL IL200822A patent/IL200822A/en not_active IP Right Cessation
- 2009-09-10 ZA ZA2009/06303A patent/ZA200906303B/en unknown
-
2011
- 2011-07-11 US US13/180,127 patent/US8497294B2/en not_active Expired - Fee Related
-
2014
- 2014-08-25 JP JP2014170885A patent/JP2015028033A/ja active Pending
- 2014-11-12 CY CY20141100938T patent/CY1115877T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200906303B (en) | 2015-08-26 |
| CY1115877T1 (el) | 2017-01-25 |
| CN101686965B (zh) | 2014-09-17 |
| CA2679878A1 (en) | 2008-09-18 |
| WO2008110846A2 (en) | 2008-09-18 |
| AU2008224657A1 (en) | 2008-09-18 |
| MX2009009874A (es) | 2009-09-24 |
| HRP20141034T1 (hr) | 2014-12-19 |
| BRPI0808802A2 (pt) | 2017-05-02 |
| RS53580B1 (sr) | 2015-02-27 |
| SI2134339T1 (sl) | 2014-12-31 |
| RU2009137779A (ru) | 2011-05-10 |
| EP2433632A1 (en) | 2012-03-28 |
| ES2511817T3 (es) | 2014-10-23 |
| KR20100014720A (ko) | 2010-02-10 |
| PT2134339E (pt) | 2014-11-03 |
| PL2134339T3 (pl) | 2015-04-30 |
| EP2134339B1 (en) | 2014-09-17 |
| GB0704932D0 (en) | 2007-04-25 |
| CN101686965A (zh) | 2010-03-31 |
| WO2008110846A3 (en) | 2009-03-05 |
| US20110269808A1 (en) | 2011-11-03 |
| JP2010521446A (ja) | 2010-06-24 |
| US20100113551A1 (en) | 2010-05-06 |
| RU2527151C2 (ru) | 2014-08-27 |
| AU2008224657B2 (en) | 2014-06-26 |
| IL200822A0 (en) | 2010-05-17 |
| DK2134339T3 (da) | 2014-11-03 |
| JP2015028033A (ja) | 2015-02-12 |
| EP2134339A2 (en) | 2009-12-23 |
| IL200822A (en) | 2016-09-29 |
| US8497294B2 (en) | 2013-07-30 |
| HK1133828A1 (en) | 2010-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ579341A (en) | Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases | |
| MX2007003603A (es) | Metodos para preparar compuestos de indazol. | |
| CL2009000443A1 (es) | Compuestos derivados de 3-metil-imidazo-[1,2-b]-piridazina, moduladores de cinasa de tirosina c-met; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades proliferativas como tumores solidos, metastasis, cancer renal, cancer de cabeza y cuello. cancer pulmon. | |
| UY30041A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
| PE20242042A1 (es) | Anticuerpos especificos para flt3 y sus usos | |
| MX2010005300A (es) | 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus. | |
| MY154969A (en) | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile | |
| MX2010010151A (es) | Moduladores de cinasa aurora y metodo de uso. | |
| GEP20125534B (en) | Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3- d]pyrimidin-4-yl)-1h-pyrazol-l-yl)-3- cyclopentyl propanenitrile | |
| EA201100425A1 (ru) | Производные пиколинамида в качестве ингибиторов киназы | |
| TW200510380A (en) | Mitotic kinesin inhibitors | |
| IL191832A (en) | Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors | |
| UA95244C2 (ru) | Соединения и способ модулирования активности киназ, и показания для их применения | |
| UY31384A1 (es) | Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b | |
| TW200801008A (en) | Protein kinase inhibitors | |
| GT200100061A (es) | Compuestos y composiciones farmaceuticas y metodos para inhibir kinasas proteinicas. | |
| TNSN08078A1 (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
| MX2009010517A (es) | Moduladores de cinasa aurora y metodos de uso. | |
| CR9647A (es) | Moduladores de cinasa de aminoquinolina y amoniquinazolina | |
| WO2010006168A3 (en) | Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor | |
| WO2007095340A3 (en) | Small-molecule modulators of trp-p8 activity | |
| MX2024004440A (es) | Moduladores de molécula pequeña de pantotenato-cinasas. | |
| BRPI0407282A (pt) | Processo para preparação de inibidores de pirrolotriazina cinase | |
| WO2006055831A3 (en) | Kinase inhibitors | |
| WO2006073734A3 (en) | Modulator of alpha-synuclein toxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED, GB Free format text: OLD OWNER(S): STEVEN JOHN WOODHEAD; DAVID CHARLES REES; MARTYN FREDERICKSON; KYLA MERRIOM GRIMSHAW Owner name: ASTEX THERAPEUTICS LIMITED, GB Free format text: OLD OWNER(S): STEVEN JOHN WOODHEAD; DAVID CHARLES REES; MARTYN FREDERICKSON; KYLA MERRIOM GRIMSHAW Owner name: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER, GB Free format text: OLD OWNER(S): STEVEN JOHN WOODHEAD; DAVID CHARLES REES; MARTYN FREDERICKSON; KYLA MERRIOM GRIMSHAW |
|
| S883 | Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant) |
Free format text: THE CHAIN OF TITLE HISTORY HAS BEEN CORRECTED TO INCLUDE THE INVENTORS (72) AS ORIGINAL APPLICANTS, THE APPLICATION HAS BEEN ASSIGNED TO THE CURRENT APPLICANT (71) |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 MAR 2015 BY CPA GLOBAL Effective date: 20121225 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2016 BY CPA GLOBAL Effective date: 20150213 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2017 BY CPA GLOBAL Effective date: 20160212 |
|
| LAPS | Patent lapsed |